Schouwenberg Bas J, Veldman Bart A, Spiering Wilko, Coenen Marieke J, Franke Barbara, Tack Cees J, de Galan Bastiaan E, Smits Paul
Department of Medicine, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands.
Pharmacogenet Genomics. 2008 Apr;18(4):369-72. doi: 10.1097/FPC.0b013e3282f70481.
Hypoglycemia unawareness has been linked to desensitization of the beta2-adrenergic receptor. Desensitization of the beta2-adrenergic receptor (ADRB2) is genetically determined by the Arg16Gly variant of this receptor. We tested the hypothesis that hypoglycemia unawareness is more common among patients homozygous for the Gly16 variant. We performed genotyping of the A265G (Arg16Gly) polymorphism in the ADRB2 gene in 85 patients with type 1 diabetes and classified them according to hypoglycemia awareness status. A total of 45 patients (53%) were homozygous for Gly16, 32 patients (38%) were heterozygous and eight patients (9%) were homozygous for Arg16. Hypoglycemia unawareness was 3.4-fold more common among patients homozygous for Gly16 than among patients with other variants of the Arg16Gly polymorphism (P=0.014). We conclude that patients with type 1 diabetes who carry two alleles of the Gly16 variant of ADRB2 are at increased risk of developing hypoglycemia unawareness. Future studies are required to confirm these results in larger, independent populations.
低血糖无意识症与β2 - 肾上腺素能受体脱敏有关。β2 - 肾上腺素能受体(ADRB2)的脱敏由该受体的Arg16Gly变异在基因上决定。我们检验了这样一个假设,即低血糖无意识症在Gly16变异纯合子患者中更为常见。我们对85例1型糖尿病患者的ADRB2基因中的A265G(Arg16Gly)多态性进行了基因分型,并根据低血糖意识状态对他们进行了分类。共有45例患者(53%)为Gly16纯合子,32例患者(38%)为杂合子,8例患者(9%)为Arg16纯合子。低血糖无意识症在Gly16纯合子患者中比在Arg16Gly多态性其他变异的患者中常见3.4倍(P = 0.014)。我们得出结论,携带ADRB2基因Gly16变异两个等位基因的1型糖尿病患者发生低血糖无意识症的风险增加。需要进一步的研究在更大的独立人群中证实这些结果。